4.7 Article

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

Henit Yanai et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)

Article Gastroenterology & Hepatology

An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis

David J. Gibson et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)

Review Gastroenterology & Hepatology

The microbiota in inflammatory bowel disease

Donal Sheehan et al.

JOURNAL OF GASTROENTEROLOGY (2015)

Article Gastroenterology & Hepatology

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

Omoniyi J. Adedokun et al.

GASTROENTEROLOGY (2014)

Review Gastroenterology & Hepatology

Review article: strategies for the management of chronic unremitting ulcerative colitis

S. J. Mehta et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)

Article Gastroenterology & Hepatology

Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission

Alessandro Armuzzi et al.

INFLAMMATORY BOWEL DISEASES (2013)

Article Gastroenterology & Hepatology

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

Kang-Moon Lee et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)

Article Pharmacology & Pharmacy

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

Ingrid Ordas et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

Article Gastroenterology & Hepatology

Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis

Lennard Y. W. Lee et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)

Article Gastroenterology & Hepatology

Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

Jean Frederic Colombel et al.

GASTROENTEROLOGY (2011)

Review Gastroenterology & Hepatology

Guidelines for the management of inflammatory bowel disease in adults

Craig Mowat et al.

Article Pharmacology & Pharmacy

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

A.A. Fasanmade et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)

Article Gastroenterology & Hepatology

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

Waqqas Afif et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)

Article Medicine, General & Internal

Infliximab for induction and maintenance therapy for ulcerative colitis

P Rutgeerts et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Review Medicine, General & Internal

Inflammatory bowel disease

DK Podolsky

NEW ENGLAND JOURNAL OF MEDICINE (2002)

Article Gastroenterology & Hepatology

Lack of common NOD2 variants in Japanese patients with Crohn's disease

N Inoue et al.

GASTROENTEROLOGY (2002)

Article Medicine, General & Internal

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

SB Hanauer et al.

LANCET (2002)

Article Gastroenterology & Hepatology

The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study

WA Faubion et al.

GASTROENTEROLOGY (2001)